Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease

ABSTRACT

Objective

To describe the reversal of peripheral iris depigmentation associated with Vogt-Koyanagi-Harada (VKH) disease.

Methods

A retrospective report of two cases.

Results

Both patients were diagnosed with a chronic recurrent VKH disease and developed bilateral peripheral iris depigmentation (BPID). The first patient is an 8-year-old girl who was treated with systemic corticosteroids, methotrexate and adjuvant rituximab infusions that induced complete remission of uveitis and reversal of peripheral iris depigmentation at the last follow-up. The second was a 6-year-old who was treated with topical and systemic corticosteroids and oral methotrexate that induced complete remission of uveitis and reversal of peripheral iris depigmentation at the last follow-up.

Conclusions

Adequate control of uveitis associated with chronic recurrent VKH disease with appropriate immunomodulatory agents and perhaps adjuvant rituximab can reverse BPID and improve the outcomes.

KEYWORDS:

• BPID
• iris atrophy
• iris depigmentation
• VKH
• Vogt-Koyanagi-Harada disease

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The author(s) reported that there is no funding associated with the work featured in this article.